Navigation Links
Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
Date:12/17/2009

NASDAQ: CRME TSX: COM

VANCOUVER, Dec. 17 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the recently-completed Phase 3 European Comparator Study (the AVRO study) evaluating vernakalant (iv) versus amiodarone for the acute conversion of atrial fibrillation met its primary endpoint.

The AVRO study achieved statistical significance in demonstrating the superiority of vernakalant (iv) over amiodarone in the conversion of atrial fibrillation to sinus rhythm within 90 minutes of the start of drug administration. Overall the data suggests that vernakalant (iv) was well-tolerated in the study population. There were no vernakalant-related deaths or cases of "Torsades de Pointes", a specific and well-characterized ventricular arrhythmia.

Cardiome expects that detailed results of this study will be presented at a scientific conference in 2010.

In April 2009, Cardiome and Merck & Co., Inc. announced a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides a Merck affiliate, Merck Sharp & Dohme Corp., with exclusive global rights to vernakalant (oral) for the maintenance of normal heart rhythm in patients with atrial fibrillation, and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to vernakalant (iv) for rapid conversion of acute atrial fibrillation to normal heart rhythm. If approved by the European regulatory authorities, Merck has exclusive rights to commercialize vernakalant (iv) in the European Union.

'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome to Release Third Quarter Results
2. Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial
3. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
4. Cardiome Pharma Corp. Announces Final Results of Tender Offer
5. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
6. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
7. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
8. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
9. Cardiome to Hold Conference Call
10. Cardiome Announces Management Transition
11. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... KY (PRWEB) , ... August 31, 2015 , ... ... Wyoming, has selected ezDI’s computer-assisted coding (CAC) software for its Clinical Documentation Improvement ... engine, ezNLP, and a patent pending ICD-10 solution - ezCAC is an enterprise-level ...
(Date:8/31/2015)... ... August 31, 2015 , ... Castle Dermatology Institute now welcomes ... Pedram Ghasri is a graduate of the University of California, Los Angeles. He graduated ... at the University of California, Irvine Medical School. As a nationally recognized Regents Scholar, ...
(Date:8/31/2015)... ... , ... “My mother and husband use oxygen therapy and the tubing irritates ... could be a comfortable way to prevent the irritation, so I invented this.” She ... more secure way to anchor the cannula tubing used in oxygen therapy and it ...
(Date:8/31/2015)... ... August 31, 2015 , ... A year ago this month, ... preparing to release a new issue commemorating the successful first year. , “We ... for a potentially difficult time in their lives,” says Melissa Wolfert, founding Publisher for ...
(Date:8/31/2015)... ... August 31, 2015 , ... There’s big news for ... digital healthcare industry. , Consumer driven health plans (CDHPs) are a growing phenomenon, ... and strategic role to the company, and another to answer customers’ questions directly. , ...
Breaking Medicine News(10 mins):Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 2Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 3Health News:Wyoming Medical Center Selects ezDI’s CAC/CDI Solution Based on Integrated Healthcare Data Management, Workflow Design and ROI 4Health News:Castle Dermatology Institute Now Welcomes Dr. Pedram Ghasri to the Practice 2Health News:InventHelp® Inventor Designs Nasal Cannula Ear Protector (AVZ-1217) 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 2Health News:Seniors Guide Magazine Celebrates Its First Year in Columbus With A Special Anniversary Issue 3Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 2Health News:ZendyHealth Adds Two Prestigious Consumer Driven Health Plan (CDHP) Experts 3
... Electronic devices of the future could be smaller, faster, ... discovery by researchers at the Department of Energy,s Oak ... published in Science , involves a method to ... decades have held tremendous promise but have eluded experimental ...
... 17 HealthTronics, Inc. ("HealthTronics") (Nasdaq: HTRN ... ) announced today that HealthTronics has commenced an exchange ... common stock pursuant to their previously-announced definitive agreement dated ... of the exchange offer, Endocare stockholders who validly tender ...
... Inclusion of General Surgeons, Otolaryngologists and , Ophthalmologists ... The American College of Surgeons (ACS) supports legislation ... Zack Space (D-Ohio), which includes the participation of general ... Loan Repayment Program called the Access to Frontline Health ...
... AMERIGROUP Corporation (NYSE: AGP ) today announced that it ... June 24 in Boston, Massachusetts. , , A live webcast ... p.m. Eastern Time, can be accessed on AMERIGROUP,s Web site, ... of the webcast will be available for 30 days after the ...
... ... Center, the most comprehensive program in Orange County. Hoag Voice and Swallowing Center provides ... , ... CA (Vocus) June 17, 2009 -- Hoag Hospital announces the grand opening of ...
... Health-privacy advocates and patient-choice supporters will discuss implications of federal ... on Thursday, June 18 at 9:00 am. Health-policy experts will ... HEALTH-PRIVACY RIGHTS: Which bills will make sure Americans are not ... and track them from cradle to grave and that citizens ...
Cached Medicine News:Health News:ORNL finding could help electronics industry enter new phase 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 2Health News:HealthTronics, Inc. Commences Exchange Offer for Endocare, Inc. Shares 3Health News:American College of Surgeons Supports Bill to Create New Frontline Providers Loan Repayment Program 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 2Health News:Innovative Voice and Swallowing Center Opens in Orange County 3
(Date:8/31/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY), a biopharmaceutical ... therapeutics for the treatment of diseases of the central ... BNC101 IND submission has passed review by the US ... a Phase 1 clinical trial in patients with metastatic ... prior to 31 December 2015. Bionomics, CEO ...
(Date:8/30/2015)... Massachusetts y LONDRES, August 30, 2015 /PRNewswire/ ... ofrece una visión holística de l ... todo el trayecto   ... hoy el debut europeo de IntelliSpace Cardiovascular , ... que ofrece sofisticadas herramientas para acceder, analizar y compartir ...
(Date:8/28/2015)... Calif. , Aug. 28, 2015  CytomX Therapeutics, ... treatment of cancer, today announced the filing of a ... and Exchange Commission (SEC) relating to a proposed initial ... shares to be offered and the price range for ... to list its common stock under the symbol "CTMX" ...
Breaking Medicine Technology:Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3CytomX Files Registration Statement for Proposed Initial Public Offering 2
... Amgen (NASDAQ: AMGN ), the world,s largest ... in Brazil, including the acquisition of Bergamo, a privately-held ... rights in Brazil to its products that were previously ... transactions will provide Amgen a significant presence in Brazil ...
... 2011 Xeridiem™ Medical Devices (xeridiem) is a ... Award (MDEA).  This international award was for a ... System (PleuraFlow ATC), developed by Clear Catheter Systems ... design and development for manufacturability, supported the regulatory ...
Cached Medicine Technology:Amgen Establishes Commercial Operations in Brazil 2Amgen Establishes Commercial Operations in Brazil 3Amgen Establishes Commercial Operations in Brazil 4Xeridiem Medical Devices Receives MD+DI 2011 Medical Design Excellence Award (MDEA). 2
Shielding's Economy Coat Apron offers the same features as our Standard Coat Apron with an open back allowing for freedom of movement, maximum flexibility and increased comfort....
Upper arm protection...
Lap pad used to protect pelvic regions...
Light and comfortable thyroid protection. The softest, most comfortable throid collar made. No neck irritating binding....
Medicine Products: